Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07673367 · ClinicalTrials.gov registry record · Phase 2
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT07673367 is a Phase 2 study that has not yet begun recruiting, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT07673367, a Phase 2 study, has not yet begun recruiting, sponsored by Vanderbilt-Ingram Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Nemtabrutinib, a BTK inhibitor, may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chimeric antigen receptor (CAR) T-cell therapy, such as brexu-cel, is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Chemotherapy, such as fludarabine and cyclophosphamide, are given before CAR T cell therapy to help kill cancer cells in the body and help make room for the CAR T cells. Giving nemtabrutinib in combination with brexu-cel may be safe, tolerable, and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.
Interventions
- DRUG Nemtabrutinib
- DRUG Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-07-31 |
| Est. Completion | 2032-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07673367
The ClinicalTrials.gov registry entry for NCT07673367 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nemtabrutinib is the first listed.
NCT07673367 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07673367 about?
NCT07673367 is a clinical study titled "Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma". This phase II trial tests the effect of nemtabrutinib in combination with brexucabtagene autoleucel (brexu-cel) in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Nemtabrutinib, a BT...
What is the current status of trial NCT07673367?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2026-07-31. Estimated completion is 2032-07-31.
What interventions are being tested in trial NCT07673367?
The interventions under investigation include: Nemtabrutinib (DRUG), Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) (DRUG).
Who is sponsoring clinical trial NCT07673367?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.